Showing results (1-10 of 91) with videos related to
Sort By:
Pageof 10
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 6, 2009
Issues in using progression-free survival when evaluating oncology productsThomas R Fleming, Mark D Rothmann, Hong Laura LuClinical Trials (London, England)|April 25, 2023
Finding the (biomarker-defined) subgroup of patients who benefit from a novel therapy: No time for a game of hide and seekLisa Meier McShane, Mark D Rothmann, Thomas R FlemingDrug Information Journal|June 23, 2012
Testing in a Prespecified Subgroup and the Intent-to-Treat PopulationMark D Rothmann, Jenny J Zhang, Laura Lu, et al.Clinical Trials (London, England)|August 13, 2011
Some essential considerations in the design and conduct of non-inferiority trialsThomas R Fleming, Katherine Odem-Davis, Mark D Rothmann, et al.Journal of Biopharmaceutical Statistics|February 26, 2010
Missing data in biologic oncology productsMark D Rothmann, Kallappa Koti, Kyung Yul Lee, et al.Lifetime Data Analysis|September 8, 2006
Inferences on a life distribution by sampling from the ages or the ages at deathMark D RothmannStatistics in Medicine|May 21, 2025
A Perspective on the Appropriate Implementation of ICH E9(R1) Addendum Strategies for Handling Intercurrent EventsThomas R Fleming, Kevin J Carroll, Janet T Wittes, et al.Journal of Biopharmaceutical Statistics|August 19, 2003
On non-inferiority analysis based on delta-method confidence intervalsMark D Rothmann, Hsiao-Hui TsouStatistics in Medicine|July 20, 2006
Standard versus adaptive monitoring procedures: A commentaryThomas R FlemingClinical Trials (London, England)|December 6, 2014
Protecting the confidentiality of interim data: addressing current challengesThomas R FlemingPageof 10